Vivoryon Therapeutics N.V.
VVY.AS · AMS
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | €0 | €0 | €0 | €0 |
| - Cash | €0 | €0 | €0 | €0 |
| + Debt | €0 | €0 | €0 | €0 |
| Enterprise Value | €0 | €0 | €0 | €0 |
| Revenue | €0 | -€0 | €0 | €0 |
| % Growth | 100% | – | -100% | – |
| Gross Profit | -€0 | -€0 | -€0 | €0 |
| % Margin | – | 85.5% | – | 83.9% |
| EBITDA | -€0 | -€0 | -€0 | -€0 |
| % Margin | – | 783.2% | – | -111.8% |
| Net Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | – | 782.9% | – | -117.6% |
| EPS Diluted | -0.79 | -1.12 | -1.28 | -0.63 |
| % Growth | 29.5% | 12.5% | -103.2% | – |
| Operating Cash Flow | -€0 | -€0 | -€0 | -€0 |
| Capital Expenditures | -€0 | -€0 | -€0 | -€0 |
| Free Cash Flow | -€0 | -€0 | -€0 | -€0 |